CNL launches program to accelerate development of



CHALK RIVER, Ontario, November 25, 2021 (GLOBE NEWSWIRE) – Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, are pleased to announce that they have issued a call for proposals for a new “health component” as part of its Canadian Nuclear Research Initiative (CNRI). The new program is designed to accelerate the development of targeted radiopharmaceuticals in Canada through collaborative research projects related to health sciences, radiobiology and medical isotope development, providing access to world-class laboratories and to the research capabilities of the Chalk River Laboratories campus.

Launched in 2019, the CNRI program was initially created by CNL to advance the deployment of small modular reactors (SMRs) and advanced reactor designs. Continued interest in the program led CNRI to expand the NCRI into health sciences, another key area of ​​expertise, allowing participants to access the company’s unique facilities and personnel to conduct research. in partnership with LNC.

“With over a billion medical treatments performed using isotopes produced at Chalk River Laboratories, CNL’s work has touched the lives of people around the world,” commented Joe McBrearty, President and Chief Executive Officer. the direction of CNL. “Today, we continue to pursue this mission as a full-service nuclear laboratory with the ability to perform cutting-edge pharmaceutical development, as well as a wide range of radiochemical analyzes. Through the expanded NCRI program, we hope to better leverage our resources to help people with a wide range of medical conditions, with a focus on cancer treatment.

For the first promotion of the program, research proposals should align with topics that include targeted delivery systems, toxicology and preclinical evaluation. Once the technical review of each proposal is complete, CNL will work with the proponent to develop a plan to establish the scope, budget and deliverables for the project. CNL will perform a final assessment of the proposed project plans before proceeding with the final selection and approval of successful applicants. The deadline for submission is January 15, 2022 and projects will be selected in spring 2022.

As a world leader in medical isotopes and related research for more than 70 years, CNL helped pioneer the use of cobalt-60 radiation therapy for the treatment of cancer and was a major producer global molybdenum-99, which is used in diagnostic procedures. CNL now has a variety of health and dosimetry capabilities, including preclinical animal studies, isotope production and processing, in vitro drug evaluation, targeted radionuclide therapies, ISO accredited analytical chemistry and waste management solutions.

“The CNRI program has been incredibly successful in the development of SMR and other advanced reactor technologies, and has encouraged us to apply this collaborative model to other areas of our research,” commented Dr. Jeff Griffin. , vice president of science and technology at CNL. . “We believe there is an unmet need for organizations that pursue research in radiopharmaceutical discovery, toxicology and preclinical efficacy, and this program can serve as a vehicle to advance innovative solutions in these areas. “

Apart from the NCRI, the CNL strive to establish itself as an international hub in the research, development and supply of next-generation medical isotopes and radiopharmaceuticals, including actinium-225, an isotope rare which shows great promise as a basis for new cutting products. cutting-edge cancer therapies. As part of these efforts, LNC recently signed a memorandum of understanding with ITM Isotope Technologies Munich SE to explore the development and industrial scale production of Actinium-225.

To learn more about CNL and their work in the health sciences, please visit www.cnl.ca/health. For more information on the NCRI Health Stream, including submission guidelines and details, please visit www.cnl.ca/cnri-health.

About CNL
Canadian Nuclear Laboratories is a world leader in nuclear science and technology, providing unique capabilities and solutions across a wide range of industries. Actively involved in industrial research and development in the fields of nuclear, transport, clean technologies, energy, defense, security and life sciences, we offer solutions to maintain the competitiveness of these sectors internationally.

With continued investments in new facilities and a focused mandate, Canadian Nuclear Laboratories is well positioned for the future. A new performance standard reinforced by a strong safety culture underlines every activity.

For more information on the full range of Canadian Nuclear Laboratories services, please visit www.cnl.ca or contact [email protected]

CNL contact:
Patrick quinn
Director, Corporate Communications
Phone: 1-866-886-2325
Email: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/869ef61d-4a19-4c86-93d9-47ca287adbd3


Previous Australian regulator authorizes takeover of Ouriginal
Next Godrej Properties purchases 16 acre plot of land in Sarjapur, Bangalore